Vaccine makers, packaged food cos slide as Trump taps RFK to head health agency
** Shares of vaccine makers tumbled at the end of Thursday's trading session as U.S. President-elect Donald Trump selected Robert F Kennedy Jr to head the Department of Health and Human Services
** BioNTech BNTX.O, Moderna MRNA.O, Pfizer PFE.N, GSK GSK.N and Sanofi SNY.O ended down between 2.1% and 7.1%
** Kennedy has made false medical claims, including that vaccines are linked to autism
** In after hours trading, the share price movement among the drugmakers was more muted
** Kennedy has also vowed to reduce the dominance of ultra-processed foods; shares of Sysco SYY.N dropped 2% for the day and Kraft Heinz KHC.O> fell 1%, while PepsiCo PEP.O pared earlier to end up 0.2%
Reporting by Stephen Culp
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
